TY - JOUR
T1 - Epidemiological Changes and Improvement in Outcomes of Infective Endocarditis in Europe in the Twenty-First Century
T2 - An International Collaboration on Endocarditis (ICE) Prospective Cohort Study (2000–2012)
AU - International Collaboration for Endocarditis (ICE) Investigators
AU - Ambrosioni, Juan
AU - Hernández-Meneses, Marta
AU - Durante-Mangoni, Emanuele
AU - Tattevin, Pierre
AU - Olaison, Lars
AU - Freiberger, Tomas
AU - Hurley, John
AU - Hannan, Margaret M.
AU - Chu, Vivian
AU - Hoen, Bruno
AU - Moreno, Asunción
AU - Cuervo, Guillermo
AU - Llopis, Jaume
AU - Miró, José M.
AU - Clara, Liliana
AU - Sanchez, Marisa
AU - Casabé, José
AU - Cortes, Claudia
AU - Nacinovich, Francisco
AU - Oses, Pablo Fernandez
AU - Ronderos, Ricardo
AU - Sucari, Adriana
AU - Thierer, Jorge
AU - Altclas, Javier
AU - Kogan, Silvia
AU - Spelman, Denis
AU - Athan, Eugene
AU - Harris, Owen
AU - Kennedy, Karina
AU - Tan, Ren
AU - Gordon, David
AU - Papanicolas, Lito
AU - Korman, Tony
AU - Kotsanas, Despina
AU - Dever, Robyn
AU - Jones, Phillip
AU - Konecny, Pam
AU - Lawrence, Richard
AU - Rees, David
AU - Ryan, Suzanne
AU - Feneley, Michael P.
AU - Harkness, John
AU - Jones, Phillip
AU - Ryan, Suzanne
AU - Jones, Phillip
AU - Ryan, Suzanne
AU - Jones, Phillip
AU - Post, Jeffrey
AU - Reinbott, Porl
AU - Lerakis, Stamatios
N1 - Funding Information:
No funding was received for the study, rapid service fee or the support from the Cardiovascular Infectious Diseases and infective endocarditis team members.
Funding Information:
José M. Miró received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–23. Margaret M. Hannan held a Rio Hortega Research Grant (CM17/00062) from the “Instituto de Salud Carlos III” and the “Ministerio de Economia y Competitividad”, Madrid (Spain) in 2018-20. Juan Ambrosioni, Marta Hernández-Meneses, Emanuele Durante-Mangoni, Pierre Tattevin, Lars Olaison, Tomas Freiberger, John Hurley, Vivian Chu, Bruno Hoen, Asunción Moreno, Guillermo Cuervo and Jaume Llopis have nothing to declare.
Funding Information:
We want to express our appreciation to all Cardiovascular Infectious Diseases and infective endocarditis team members for their contribution to this work and their precious task and effort in clinical care and daily practice with all our patients. No funding was received for the study, rapid service fee or the support from the Cardiovascular Infectious Diseases and infective endocarditis team members. Juan Ambrosioni, Marta Hernández-Meneses, Emanuele Durante-Mangoni, Pierre Tattevin, Lars Olaison, Tomas Freiberger, John Hurley, Margaret M. Hannan, Vivian Chu, Bruno Hoen, Asunción Moreno, Guillermo Cuervo, Jaume Llopis and José M. Miró contributed to the design and development of the study and to the acquisition, analysis, and interpretation of the results. All authors contributed to producing the article, by drafting the work or revising it critically. All authors have had access to the final version and have approved it to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were properly investigated and resolved. This work was presented, in part, at the 14th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, Dublin, Ireland, 22-24 June 2017; abstract 51. José M. Miró received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–23. Margaret M. Hannan held a Rio Hortega Research Grant (CM17/00062) from the “Instituto de Salud Carlos III” and the “Ministerio de Economia y Competitividad”, Madrid (Spain) in 2018-20. Juan Ambrosioni, Marta Hernández-Meneses, Emanuele Durante-Mangoni, Pierre Tattevin, Lars Olaison, Tomas Freiberger, John Hurley, Vivian Chu, Bruno Hoen, Asunción Moreno, Guillermo Cuervo and Jaume Llopis have nothing to declare. The Institutional Review Board (IRB) of the Hospital Clinic of Barcelona approved the implementation of this study (ERB number HCB/2004/4629). The study’s retrospective nature waived the requirement for informed written consent. Patient identification was encoded, complying with the needs of the Organic Law on Data Protection 15/1999. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/4
Y1 - 2023/4
N2 - Introduction: Infective endocarditis (IE) has undergone important changes in its epidemiology worldwide. Methods: The study aimed to compare IE epidemiological features and outcomes according to predefined European regions and between two different time periods in the twenty-first century. Results: IE cases from 13 European countries were included. Two periods were considered: 2000–2006 and 2008–2012. Two European regions were considered, according to the United Nations geoscheme for Europe: Southern (SE) and Northern–Central Europe (NCE). Comparisons were performed between regions and periods. A total of 4195 episodes of IE were included, 2113 from SE and 2082 from NCE; 2787 cases were included between 2000 and 2006 and 1408 between 2008 and 2012. Median (IQR) age was 63.7 (49–74) years and 69.4% were males. Native valve IE (NVE), prosthetic valve IE (PVE), and device-related IE were diagnosed in 68.3%, 23.9%, and 7.8% of cases, respectively; 52% underwent surgery and 19.3% died during hospitalization. NVE was more prevalent in NCE, whereas device-related IE was more frequent in SE. Higher age, acute presentation, hemodialysis, cancer, and diabetes mellitus all were more prevalent in the second period. NVE decreased and PVE and device-related IE both increased in the second period. Surgical treatment also increased from 48.7% to 58.4% (p < 0.01). In-hospital and 6-month mortality rates were comparable between regions and significantly decreased in the second period. Conclusions: Despite an increased complexity of IE cases, prognosis improved in recent years with a significant decrease in 6-month mortality. Outcome did not differ according to the European region (SE versus NCE). Graphical Abstract: [Figure not available: see fulltext.]
AB - Introduction: Infective endocarditis (IE) has undergone important changes in its epidemiology worldwide. Methods: The study aimed to compare IE epidemiological features and outcomes according to predefined European regions and between two different time periods in the twenty-first century. Results: IE cases from 13 European countries were included. Two periods were considered: 2000–2006 and 2008–2012. Two European regions were considered, according to the United Nations geoscheme for Europe: Southern (SE) and Northern–Central Europe (NCE). Comparisons were performed between regions and periods. A total of 4195 episodes of IE were included, 2113 from SE and 2082 from NCE; 2787 cases were included between 2000 and 2006 and 1408 between 2008 and 2012. Median (IQR) age was 63.7 (49–74) years and 69.4% were males. Native valve IE (NVE), prosthetic valve IE (PVE), and device-related IE were diagnosed in 68.3%, 23.9%, and 7.8% of cases, respectively; 52% underwent surgery and 19.3% died during hospitalization. NVE was more prevalent in NCE, whereas device-related IE was more frequent in SE. Higher age, acute presentation, hemodialysis, cancer, and diabetes mellitus all were more prevalent in the second period. NVE decreased and PVE and device-related IE both increased in the second period. Surgical treatment also increased from 48.7% to 58.4% (p < 0.01). In-hospital and 6-month mortality rates were comparable between regions and significantly decreased in the second period. Conclusions: Despite an increased complexity of IE cases, prognosis improved in recent years with a significant decrease in 6-month mortality. Outcome did not differ according to the European region (SE versus NCE). Graphical Abstract: [Figure not available: see fulltext.]
KW - Cardiac surgery
KW - Epidemiology
KW - Europe
KW - Infective endocarditis
KW - Mortality
UR - http://www.scopus.com/inward/record.url?scp=85156139109&partnerID=8YFLogxK
U2 - 10.1007/s40121-023-00763-8
DO - 10.1007/s40121-023-00763-8
M3 - Article
AN - SCOPUS:85156139109
SN - 2193-8229
VL - 12
SP - 1083
EP - 1101
JO - Infectious Diseases and Therapy
JF - Infectious Diseases and Therapy
IS - 4
ER -